Literature DB >> 27538409

Single-Center Experience on Liver Transplantation for Model for End-Stage Liver Disease Score 40 Patients.

Georgios C Sotiropoulos1, Spyridon Vernadakis2, Andreas Paul2, Dieter P Hoyer2, Fuat H Saner2, Anja Gallinat2.   

Abstract

BACKGROUND: Organ shortage and waiting list mortality have led to changes in the allocation policy in Eurotransplant. AIM: To identify factors influencing the survival of liver transplanted patients with model for end-stage liver disease (MELD) score of 40. PATIENTS AND METHODS: Data of listed adult patients who reached a MELD score 40 in the period 12/2006-06/2010 were reviewed. Donor/graft and recipient characteristics, and operative details were analyzed. Statistical analysis encompassed Kaplan-Meier analysis/log-rank test as well as univariate and multivariable regression analyses.
RESULTS: Forty-eight patients achieved a MELD score 40. Thirty patients were transplanted, whereas 18 patients were not. Three-month, 1-year, and 5-year patient and graft survival for transplanted patients was 53, 50, and 47 %, respectively. Three-month and 1-year survival after listing was 11 and 6 % for not transplanted patients, respectively (p < 0.0001). Multivariable analysis revealed pre-operative dialysis (p = 0.0246) and portal vein thrombosis (PVT) (p = 0.0231) to be independent prognostic factors for post-transplant patient survival. A point scoring system was created, which reached statistical significance (p = 0.0007). One-year and 5-year survival for scores 0, 1, and 2 were 72 and 64, 42 and 42 and 0 %, respectively. There was no statistical difference in transplantation costs between patients who survived or died (p = 0.1578).
CONCLUSIONS: At our center, coexistence of pre-operative dialysis and PVT represents a clear contraindication for LT regarding MELD score 40 patients.

Entities:  

Keywords:  Hospital mortality; Liver transplantation; MELD score; Sickest first policy; Survival benefit

Mesh:

Year:  2016        PMID: 27538409     DOI: 10.1007/s10620-016-4274-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis.

Authors:  Philipp Dutkowski; Christian E Oberkofler; Markus Béchir; Beat Müllhaupt; Andreas Geier; Dimitri A Raptis; Pierre-Alain Clavien
Journal:  Liver Transpl       Date:  2011-06       Impact factor: 5.799

2.  Impact of the MELD allocation after its implementation in liver transplantation.

Authors:  Christoph Benckert; Markus Quante; Armin Thelen; Michael Bartels; Sven Laudi; Thomas Berg; Udo Kaisers; Sven Jonas
Journal:  Scand J Gastroenterol       Date:  2011-03-28       Impact factor: 2.423

3.  Early post-transplant survival: Interaction of MELD score and hospitalization status.

Authors:  Therese Bittermann; George Makar; David S Goldberg
Journal:  J Hepatol       Date:  2015-04-07       Impact factor: 25.083

4.  Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept.

Authors:  Tobias J Weismüller; Panagiotis Fikatas; Jan Schmidt; Ana P Barreiros; Gerd Otto; Susanne Beckebaum; Andreas Paul; Markus N Scherer; Hartmut H Schmidt; Hans J Schlitt; Peter Neuhaus; Jürgen Klempnauer; Johann Pratschke; Michael P Manns; Christian P Strassburg
Journal:  Transpl Int       Date:  2010-09-03       Impact factor: 3.782

5.  High model for end-stage liver disease score as a predictor of survival during long-term follow-up after liver transplantation.

Authors:  H Suzuki; A S R Bartlett; P Muiesan; W Jassem; M Rela; N Heaton
Journal:  Transplant Proc       Date:  2012-03       Impact factor: 1.066

6.  A high model for end-stage liver disease score should not be considered a contraindication to living donor liver transplantation.

Authors:  K-S Poon; T-H Chen; L-B Jeng; H-R Yang; P-C Li; C-C Lee; C-C Yeh; H-C Lai; W-P Su; C Y Peng; Y-F Chen; Y-J Ho; P-P Tsai
Journal:  Transplant Proc       Date:  2012-03       Impact factor: 1.066

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

8.  The survival benefit of liver transplantation.

Authors:  Robert M Merion; Douglas E Schaubel; Dawn M Dykstra; Richard B Freeman; Friedrich K Port; Robert A Wolfe
Journal:  Am J Transplant       Date:  2005-02       Impact factor: 8.086

9.  Survival benefit of liver transplantation and the effect of underlying liver disease.

Authors:  Ana L Gleisner; Alvaro Muñoz; Ajacio Brandao; Claudio Marroni; Maria Lucia Zanotelli; Guido Gracco Cantisani; Leila Beltrami Moreira; Michael A Choti; Timothy M Pawlik
Journal:  Surgery       Date:  2009-12-03       Impact factor: 3.982

10.  Liver transplantation in highest acuity recipients: identifying factors to avoid futility.

Authors:  Henrik Petrowsky; Abbas Rana; Fady M Kaldas; Anuj Sharma; Johnny C Hong; Vatche G Agopian; Francisco Durazo; Henry Honda; Jeffrey Gornbein; Victor Wu; Douglas G Farmer; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2014-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.